RXI-109 treatment to reduce the formation of hypertrophic dermal scars

被引：1
|
作者：
Barefoot, L. [1 ]
Survi, M. [1 ]
Cardia, J. [1 ]
Bulock, K. [1 ]
Dispersyn, G. [1 ]
机构：
[1] RXI Pharmaceut Corp, Marlborough, MA USA
来源：
JOURNAL OF INVESTIGATIVE DERMATOLOGY | 2018年 / 138卷 / 05期
关键词：
D O I：
10.1016/j.jid.2018.03.503
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
496
引用
收藏
页码：S84 / S84
页数：1
相关论文
共 50 条
  • [1] Update on phase 2 clinical trial results of RXI-109 treatment to reduce the formation of hypertrophic dermal scars
    Libertine, Lyn
    Pavco, Pamela
    Young, V. Leroy
    Paz, Nelly Georgina
    Hunstad, Joseph
    Cauwenbergh, Geert
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2015, 72 (05) : AB273 - AB273
  • [2] RXI-109 treatment to reduce the formation of keloids following keloidectomy
    Pavco, Pamela
    Libertine, Lyn
    Young, V. Leroy
    Woolery-Lloyd, Heather
    Cauwenbergh, Geert
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2015, 72 (05) : AB273 - AB273
  • [3] RXI-109 Treatment for Proliferative Vitreoretinopathy (PVR) and other Ocular Disorders
    Libertine, Lyn
    Lewis, Geoffrey P.
    Luna, Gabriel
    Fisher, Steven K.
    Cardia, James
    Panderarinathan, Lakshmipathi
    Bulock, Karen
    Pavco, Pamela A.
    Byrne, Michael
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2014, 55 (13)
  • [4] RXI-109 reduces a key component of dermal scarring, connective tissue growth factor mRNA, in a multidose phase 1 clinical trial
    Libertine, Lyn
    Cauwenbergh, Geert
    Bulock, Karen
    Holton, Katherine
    Paz, Nelly
    Pavco, Pamela
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2014, 70 (05) : AB196 - AB196
  • [5] EXOGENOUS ELECTRIC-CURRENT CAN REDUCE THE FORMATION OF HYPERTROPHIC SCARS
    WEISS, DS
    EAGLSTEIN, WH
    FALANGA, V
    JOURNAL OF DERMATOLOGIC SURGERY AND ONCOLOGY, 1989, 15 (12): : 1272 - 1275
  • [6] The RNAi compound RXI-109 reduces connective tissue growth factor, a key component of dermal scarring, at incision sites in a first-in-human phase 1 clinical trial
    Pavco, Pamela
    Cauwenbergh, Geert
    Bulock, Karen
    Young, Leroy
    Libertine, Lyn
    Byrne, Michael
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2014, 70 (05) : AB196 - AB196
  • [7] A Phase 1/2 multidose, dose escalation study to evaluate RXI-109 administered by intravitreal injection to reduce the progression of subretinal fibrosis in subjects with advanced neovascular AMD (NVAMD)
    Byrne, Michael
    Gagne, Natalie
    Hafiz, Gulnar
    Mir, Tahreem
    Survi, Manasa
    Barefoot, Laurie
    Cardia, James
    Bulock, Karen
    Pavco, Pamela A.
    Campochiaro, Peter A.
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2017, 58 (08)
  • [8] On the surgical treatment of hypertrophic scars: a comprehensive guideline for the surgical treatment of hypertrophic scars
    Stekelenburg, C. M.
    Van der Wal, M. B. A.
    Middelkoop, E.
    Niessen, F. B.
    Van Zuijlen, P. P. M.
    EUROPEAN SURGERY-ACTA CHIRURGICA AUSTRIACA, 2012, 44 (02): : 79 - 84
  • [9] On the surgical treatment of hypertrophic scars: a comprehensive guideline for the surgical treatment of hypertrophic scars
    C. M. Stekelenburg
    M. B. A. Van der Wal
    E. Middelkoop
    F. B. Niessen
    P. P. M. Van Zuijlen
    European Surgery, 2012, 44 : 79 - 84
  • [10] Quantitative study of dermal vessels in hypertrophic scars and keloids
    Amadeu, TP
    Braune, A
    Mandarim-de-Lacerda, CA
    Desmoulière, A
    Costa, A
    FASEB JOURNAL, 2002, 16 (05): : A1209 - A1209
12345